- Home
- MTCH vs PTGX Comparison
MTCH vs PTGX Comparison
Compare MTCH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTCH | PTGX |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.3B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MTCH | PTGX |
|---|---|---|
| Price | $46.39 | $139.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 14 |
| Target Price | $42.06 | ★ $178.21 |
| AVG Volume (30 Days) | ★ 2.9M | 714.4K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 17.82 | N/A |
| EPS | 1.37 | ★ 2.35 |
| Revenue | ★ $3,487,197,000.00 | N/A |
| Revenue This Year | N/A | $1,077.07 |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | ★ $33.87 | $58.49 |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $28.81 | $73.08 |
| 52 Week High | $46.49 | $160.81 |
Technical Indicators
Market Signals| Indicator | MTCH | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 70.72 | 50.64 |
| Support Level | $29.66 | $135.10 |
| Resistance Level | N/A | $142.20 |
| Average True Range (ATR) | 1.18 | 5.90 |
| MACD | 0.57 | -0.06 |
| Stochastic Oscillator | 95.62 | 54.58 |
Price Performance
Historical ComparisonAbout MTCH Match Group Inc.
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. It generates the majority of its revenue from the Tinder segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.